SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001193125-24-032037
Filing Date
2024-02-12
Accepted
2024-02-12 16:09:31
Documents
2
Group Members
ANSBERT GADICKELUKE EVNINMPM ASSET MANAGEMENT INVESTORS BV2014 LLCMPM ASSET MANAGEMENT LLCMPM BIOIMPACT LLCMPM BIOVENTURES 2014 (B), L.P.MPM BIOVENTURES 2014 GP LLCMPM BIOVENTURES 2014 LLCONCOLOGY IMPACT FUND (CAYMAN) MANAGEMENT LPTODD FOLEYUBS ONCOLOGY I

Document Format Files

Seq Description Document Type Size
1 SC 13D/A d777936dsc13da.htm SC 13D/A 237774
2 EX-99.C d777936dex99c.htm EX-99.C 17382
  Complete submission text file 0001193125-24-032037.txt   257283
Mailing Address C/O MPM ASSET MANAGEMENT LLC 450 KENDALL STREET CAMBRIDGE MA 02142
Business Address C/O MPM ASSET MANAGEMENT LLC 450 KENDALL STREET CAMBRIDGE MA 02142 (617) 425-9200
MPM BioVentures 2014, L.P. (Filed by) CIK: 0001609492 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A

Mailing Address 611 GATEWAY BOULEVARD, SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address 611 GATEWAY BOULEVARD, SUITE 400 SOUTH SAN FRANCISCO CA 94080 (650) 443-7400
Harpoon Therapeutics, Inc. (Subject) CIK: 0001708493 (see all company filings)

IRS No.: 473458693 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-90935 | Film No.: 24619951
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)